Advancing our lead wholly owned programs for the treatment of severe inflammatory disease

We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our PD-1 agonist program; and ANB032, our BTLA agonist program, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

We recently announced the advancement of –

• Rosnilimab, our PD-1 agonist program, into a global Phase 2b trial to treat rheumatoid arthritis with study initiation in Q3 2023
• ANB032, our BTLA agonist program, into a global Phase 2b trial to treat atopic dermatitis with study initiation in Q2 2023

Continuing imsidolimab development in GPP and outlicensing plans for legacy cytokine antagonist programs

We are advancing imsidolimab, our anti-IL-36r antibody, for the treatment of generalized pustular psoriasis (GPP), and we are planning to outlicense imsidolimab prior to potential FDA approval.

Etokimab, our anti-IL-33 antagonist antibody, is Phase 2/3-ready for the treatment of respiratory disorders and is available for outlicensing.

Identifying emerging target biology opportunities in inflammation and expanding our proprietary pipeline by generating new antibody product candidates using our technology platform

We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement. Using our proprietary antibody generation platform, we are able to rapidly develop novel therapeutic antibodies against emerging targets. Our goal is to advance multiple additional wholly owned new therapeutic antibody program to IND submission.

Retaining rights to strategic products in key commercial markets

We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development and commercialization.